Physician profile
Yi Ngai
NPI 1578625737
$22,233.11
in general payments reported to CMS, 2019-2025
38 companies · $913 in 2025
The $913 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,448 · 2020: $2,889 · 2021: $4,027 · 2022: $3,778 · 2023: $3,384 · 2024: $3,794 · 2025: $913.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,091.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,090.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $3,099.48 | 2019-2025 | Vemlidy |
| Abbvie INC. | $2,329.59 | 2019-2025 | |
| Amgen INC. | $1,943.19 | 2019-2025 | Evenity, Prolia, Repatha |
| Astrazeneca Pharmaceuticals LP | $1,659.59 | 2019-2025 | Airsupra, Farxiga |
| Amarin Pharma, INC. | $1,586.33 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,378.78 | 2019-2025 | Jardiance, Ofev, Synjardy |
| Novo Nordisk INC | $1,333.13 | 2019-2025 | Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $1,185.34 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $911.07 | 2019-2023 | Belsomra, Verquvo, Steglatro |
| Sanofi-Aventis U.S. LLC | $822.90 | 2019-2023 | |
| Lilly USA, LLC | $740.85 | 2019-2024 | Mounjaro |
| Ironwood Pharmaceuticals, INC | $674.40 | 2019-2025 | Linzess |
| Bayer Healthcare Pharmaceuticals INC. | $531.14 | 2022-2025 | |
| Glaxosmithkline, LLC. | $472.62 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Ardelyx, INC. | $446.35 | 2022-2025 | Ibsrela |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yi Ngai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.